Veru (NASDAQ:VERU) Now Covered by B. Riley

Analysts at B. Riley assumed coverage on shares of Veru (NASDAQ:VERU - Get Free Report) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $5.00 price target on the stock. B. Riley's price target would indicate a potential upside of 240.14% from the company's previous close.

Several other research firms have also recently commented on VERU. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of Veru in a research note on Monday. Raymond James initiated coverage on shares of Veru in a research note on Thursday, March 28th. They issued an "outperform" rating and a $3.00 target price on the stock. Finally, Oppenheimer reissued an "outperform" rating and issued a $5.00 price objective (down from $7.00) on shares of Veru in a report on Monday, April 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $4.00.

Veru Stock Performance

Shares of NASDAQ:VERU traded up $0.14 during mid-day trading on Tuesday, hitting $1.47. 2,678,208 shares of the company traded hands, compared to its average volume of 2,384,087. The firm's 50 day simple moving average is $1.05 and its 200 day simple moving average is $0.82. The firm has a market cap of $215.18 million, a P/E ratio of -4.32 and a beta of -0.47. Veru has a 52-week low of $0.36 and a 52-week high of $1.92.

Veru (NASDAQ:VERU - Get Free Report) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.09) earnings per share for the quarter. Veru had a negative net margin of 265.27% and a negative return on equity of 130.13%. The firm had revenue of $2.14 million during the quarter. Equities research analysts expect that Veru will post -0.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Veru

Several large investors have recently added to or reduced their stakes in the stock. Worth Venture Partners LLC bought a new stake in Veru in the 4th quarter valued at about $616,000. AIGH Capital Management LLC acquired a new stake in Veru in the 4th quarter valued at approximately $2,476,000. ADAR1 Capital Management LLC acquired a new position in Veru during the 4th quarter worth $360,000. Octagon Capital Advisors LP bought a new position in shares of Veru in the fourth quarter worth $2,736,000. Finally, Perceptive Advisors LLC increased its holdings in shares of Veru by 412.4% during the fourth quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company's stock valued at $4,021,000 after purchasing an additional 4,494,821 shares during the period. 47.16% of the stock is owned by institutional investors and hedge funds.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.